Prothena

SME

Prothena

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Prothena

Address

Dublin, Ireland

Contact

info@prothena.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Prothena

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Prothena last news

26/01/2024

Hear from Prothena CEO Gene Kinney on the progress made across the Alzheimer's disease industry and his outlook for 2024

From selecting appropriate patients for clinical studies, to identifying the right endpoints and biomarkers, 2023 was marked with the very first disease-modifying treatments for Alzheimer's disease. Looking ahead in 2024, the field is poised to do an even better job of slowing the relentless disease progression of Alzheimer's disease.   As we gear up for […] The post Hear from Prothena CEO Gene Kinney on the progress made across the Alzheimer's disease industry and his outlook for 2024 first appeared on Prothena .

30/11/2023

Prothena Participates in the Walk to End Alzheimer's

Held annually in more than 600 communities nationwide, the Alzheimer's Association Walk to End Alzheimer's® is the world's largest event to raise awareness and funds for Alzheimer's care, support and research. Last month, Prothenians showed their support by participating in walks across the globe – including Dublin, San Francisco, San Diego, Philadelphia and Boston. As […] The post Prothena Participates in the Walk to End Alzheimer's first appeared on Prothena .

14/11/2023

Reflecting on CTAD 2023, and the inspiring progress of Alzheimer's disease R&D this year

Over 25 Prothenians attended the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting in October in Boston, Massachusetts. As always, it was inspiring to join experts in the space to discuss the latest advances in Alzheimer's disease R&D as we work toward a shared goal of delivering better treatments to patients. Throughout the year […] The post Reflecting on CTAD 2023, and the inspiring progress of Alzheimer's disease R&D this year first appeared on Prothena .